TCM
NPCE icon

Topline Capital Management’s Neuropace NPCE Stock Holding History

Topline Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,945
Closed -$1.06M – 43
2026
Q1 		$1.06M Buy
+80,945
New +$1.21M 0.18% 34

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Topline Capital Management's NPCE Position: Q2 2026 in Review

Topline Capital Management sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 80,945 shares — an estimated $1.06M sold.

Topline Capital Management first reported a position in NPCE in Q1 2026 and held it in 1 quarter. The position peaked at $1.06M in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Topline Capital Management reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • Topline Capital Management sold 80,945 Neuropace shares in Q2 2026, an estimated $1.06M.
  • Topline Capital Management first reported a position in Neuropace in Q1 2026 and held it in 1 quarter.
  • Topline Capital Management's Neuropace position peaked at $1.06M in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Topline Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.